About the Authors
- Robert Bissonnette
-
* E-mail: rbissonnette@innovaderm.ca
Affiliation Innovaderm Research, Montreal, Quebec, Canada
- Mayte Suárez-Fariñas
-
Affiliation Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, United States of America
- Xuan Li
-
Affiliation Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, United States of America
- Kathleen M. Bonifacio
-
Affiliation Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, United States of America
- Carrie Brodmerkel
-
Affiliation Janssen Research & Development, LLC, Spring House, Pennsylvania, United States of America
- Judilyn Fuentes-Duculan
-
Affiliation Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, United States of America
- James G. Krueger
-
Affiliation Laboratory of Investigative Dermatology, Rockefeller University, New York, New York, United States of America
Competing Interests
The authors have the following interests: This study was funded and medication provided by Janssen Inc. Canada. Author Carrie Brodmerkel is employed by Janssen Research & Development, LLC. Author Robert Bissonnette is employed by Innovaderm Research, Montreal. By grants given to Rockefeller University, Centocor/Janssen has supported specific research projects, as well as partial salary for a clinical research fellow, in his laboratory at Rockefeller University. An investigator-initiated trial is now being performed with ustekinumab in atopic dermatitis with funding to Rockefeller University from Janssen. RB have been a speaker, consultant, advisory board member and investigator and have received Honoria and grants from Janssen Inc. Abbvie, Amgen, Celgene, GSK-Steifel, Incyte, Leo Pharma, Merck, Novartis, Tribute, Valeant, Eli-Lilly, Galderma, Xenoport, Apopharma, Dermira, Incyte, Leo Pharma, Merck, Novartis, Pfizer, Tribute. RB is a shareholder of of Innovaderm Research. JGK has served as a consultant to Centocor/Janssen on matters related to the study drug (ustekinumab) and to other inflammation modulators. The consulting has resulted in compensation of $ < 5000 per year and is thus under the conflict of interest reporting levels as established by Rockefeller University and the NIH. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RB JGK. Performed the experiments: CB KMB JFD RB XL. Analyzed the data: RB MSF CB JGK. Contributed reagents/materials/analysis tools: RB JGK CB. Wrote the paper: RB JGK.